Featured Publications
Myelin Oligodendrocyte Glycoprotein–Associated Disorders
Longbrake E. Myelin Oligodendrocyte Glycoprotein–Associated Disorders. CONTINUUM Lifelong Learning In Neurology 2022, 28: 1171-1193. PMID: 35938661, PMCID: PMC9523511, DOI: 10.1212/con.0000000000001127.Peer-Reviewed Original ResearchConceptsAcute disseminated encephalomyelitisClinical spectrumCentral nervous system autoimmune diseaseNatural historyFuture therapeutic trialsLarge cohort studyRecent case reportsDistinct clinical phenotypesDisseminated encephalomyelitisGlycoprotein autoantibodiesOptic neuritisCohort studyMost patientsRelapse patternsNeuromyelitis opticaTherapeutic trialsMultiple sclerosisAutoimmune diseasesCNS diseaseCase reportCNS diseasesAccurate diagnosisClinical phenotypeDiseaseDisordersDifferential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity
Shinoda K, Li R, Rezk A, Mexhitaj I, Patterson K, Kakara M, Zuroff L, Bennett J, von Büdingen H, Carruthers R, Edwards K, Fallis R, Giacomini P, Greenberg B, Hafler D, Ionete C, Kaunzner U, Lock C, Longbrake E, Pardo G, Piehl F, Weber M, Ziemssen T, Jacobs D, Gelfand J, Cross A, Cameron B, Musch B, Winger R, Jia X, Harp C, Herman A, Bar-Or A. Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2207291120. PMID: 36634138, PMCID: PMC9934304, DOI: 10.1073/pnas.2207291120.Peer-Reviewed Original ResearchConceptsEarly disease activityDisease activityCD8 T cellsT cellsCD20 therapyPeripheral blood mononuclear cellsCellular immune profilesNew disease activityMS disease activityT cell poolMultiple sclerosis patientsAnti-inflammatory profileBlood mononuclear cellsTreatment-associated changesMultiparametric flow cytometryCentral nervous systemFurther dosingRepeat infusionsImmune profileMS patientsSclerosis patientsValidation cohortMononuclear cellsRelapse developmentImmune cascade
2016
Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity
Longbrake EE, Cross AH. Effect of Multiple Sclerosis Disease-Modifying Therapies on B Cells and Humoral Immunity. JAMA Neurology 2016, 73: 1-7. PMID: 26720195, DOI: 10.1001/jamaneurol.2015.3977.Peer-Reviewed Original ResearchConceptsDisease-modifying therapiesB cell immunityB cellsMultiple sclerosisAnti-inflammatory cytokine interleukin-10B-cell-depleting agentsMultiple Sclerosis Disease-Modifying TherapiesMost disease-modifying therapiesCytokine interleukin-10Memory B cellsB cell functionB-cell phenotypeB cell expressionB cell productionNaive B cellsMagnetic resonance imagingB cell precursorsClinical courseTherapeutic trialsInterleukin-10Proinflammatory cytokinesHumoral immunityClinical activityTherapeutic interventionsResonance imaging